MOUSE MACROPHAGE HEMAGGLUTININ (SHEEP ERYTHROCYTE RECEPTOR) WITH SPECIFICITY FOR SIALYLATED GLYCOCONJUGATES CHARACTERIZED BY A MONOCLONAL ANTIBODY

By PAUL R. CROCKER AND SIAMON GORDON

From the Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE United Kingdom

The functions of resident macrophages (MØ)\(^1\) in hematopoietic and lymphoid organs are poorly understood. In several species, in situ immunocytochemical staining with MØ-specific mAbs has demonstrated that these tissues contain large numbers of stromal MØ, even in the absence of overt inflammation or immune stimulation (1–6). We and others have previously speculated that stromal MØ may perform diverse local homeostatic functions, including regulation of growth, differentiation and movement of hematopoietic and lymphoid cells (7, 8). Our experimental approach has been to isolate the relevant MØ populations and determine whether they possess novel features that could be involved in cellular interactions.

We have focused on murine bone marrow, since this tissue contains an arborizing network of stromal MØ that establish intimate adhesive contacts with proliferating erythroid and myeloid cells (1, 7). After their isolation, the majority of resident bone marrow MØ express a novel receptor, sheep erythrocyte receptor (SER), which mediates the binding, but not ingestion, of unopsonized sheep erythrocytes (E) (9). Since it is possible that SER normally interacts with a homologous ligand on mouse bone marrow cells it was of interest to characterize its properties and distribution.

SER is a divalent cation-independent, lectin-like hemagglutinin that recognizes sialylated glycoconjugates on the erythrocyte surface. Its properties are similar to the “ganglioside receptor” on rat MØ described by Riedl and colleagues (10). In addition to resident bone marrow MØ, the receptor is expressed at high levels on isolated stromal lymph node MØ but it is low or undetectable on monocytes or peritoneal, pleural, and bronchoalveolar MØ. These features indicate that SER may be involved in interactions of stromal MØ with ligands on neighboring cells or extracellular matrix components.

This work was supported by a grant from the Medical Research Council, UK. P. R. Crocker is a Beit Memorial Fellow. We are grateful to Miss Z. Valasek for assistance with mAb production, Drs. V. H. Perry and G. Milon for help with the immunocytochemical analysis, and Dr. A. McWilliam for critical reading of the manuscript. We also thank Mr. J. Kent for superb assistance with animals, Mr. S. Buckingham and Miss C. Lee for photography, and Mrs. E. Gregory for preparation of the manuscript. Address correspondence to P. R. Crocker, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE United Kingdom.

Abbreviations used in this paper: Ag, antigen; CR3, complement receptor type 3; DAB, diaminobenzidine; LC, leukocyte common; MØ, macrophage; SER, sheep erythrocyte receptor; SER-4 Ag, the antigen recognized by mAb SER-4; TPM, thioglycollate-elicited peritoneal macrophages.
To understand the nature and functions of SER, it would clearly be advantageous to raise an mAb to the receptor. The recent observation that high levels of SER are induced on peritoneal MØ cultivated in mouse serum provided us with a suitable source of antigenic material and a rapid method for screening inhibitory mAbs (11). In this paper we describe the isolation of mAb SER-4, characterize the molecular nature of SER, and determine its distribution on MØ in various tissues.

Materials and Methods

Animals. Female C57Bl/6 mice were bred at the Sir William Dunn School of Pathology, Oxford University and used at 2-4 mo. Specific pathogen-free female AO rats were bred in the MRC Cellular Immunology Unit, Oxford University and used at 3-6 mo.

Reagents. M1/9.3, a rat pan antileukocyte common (LC) antigen (Ag) mAb (12), was provided by Dr. R. S. Steinman, The Rockefeller University (New York, NY), MOMA-1, a rat mAb that recognizes marginal metallophil cells of the spleen (13), was kindly supplied by Dr. G. Kraal, Free University, Amsterdam, The Netherlands. 1A10, a rat mAb directed to an Ag on guinea pig neutrophils (14) from Dr. H. Rosen in our laboratory was used as a negative control in immunoprecipitation and immunocytochemistry experiments. From Sigma Chemical Co. (Poole, United Kingdom) we obtained BSA, glucose oxidase, iodoacetamide, PMSF, EDTA, pepstatin, and soybean trypsin inhibitor. Lactoperoxidase was obtained from Boehringer Corp., Lewes, United Kingdom. FCS was purchased from Imperial Laboratories, Salisbury, United Kingdom. Iscove's modification of Dulbecco's Medium and Hepes buffer were obtained from Gibco Laboratories, Paisley, Scotland. Carrier-free Na\textsuperscript{25}I, [\textsuperscript{35}S]methionine (code SJ.204) and [\textsuperscript{35}S]cysteine (code SJ.232) were purchased from Amersham International PLC, Amersham, UK. Protein A-Sepharose was from Pharmacia Fine Chemicals, Hounslow, UK.

Cells. Thioglycollate-elicited peritoneal MØ (TPM) were obtained 4 d after intraperitoneal injection of 1 ml Brewer's complete thioglycollate broth. Resident bone marrow MØ were isolated by collagenase digestion of femoral bone marrow plugs, selective adherence of purified clusters to glass coverslips, and removal of attached hematopoietic cells (7).

Sheep Erythrocyte Rosetting Assays. These were carried out as described previously (11). Briefly, 2 x 10\textsuperscript{4} TPM were added to each well of a 96-well tissue culture microtiter plate (Falcon Labware, Lincoln Park, N J) and cultured for 3-4 d in 100 μl DME containing 15% mouse serum prepared as previously described (11). After washing with DME + 0.1% BSA, 20 mM Hepes, sheep E were added at 0.5% vol/vol and the plates incubated at 37°C for 30 min. Nonadherent sheep E were removed by repeated washing with medium and the percentage of MØ binding > 4 E was determined. In some experiments, rosetting assays were carried out with MØ on coverslips (9).

Production of mAb SER-4. AO rats were immunized intramuscularly three times at 10-d intervals with 10\textsuperscript{7} TPM that had been cultured for 3 d in 15% mouse serum to induce SER (11). Before injection, TPM were scraped from dishes and washed three times in PBS to remove mouse serum. The first injection was with complete and subsequent injections with IFA. Rats were boosted intravenously with 5 x 10\textsuperscript{5} mouse serum-induced TPM 3 d before fusion of spleen cells with the rat myeloma line Y3 (15). Hybridoma supernatants were screened for their ability to prevent rosette formation to mouse serum–induced TPM using the microtiter assay described above. One positive supernatant was identified from a total of >2,500 in four separate fusions and the hybridoma, designated SER-4, was cloned three times by limiting dilution. The isotype of mAb SER-4 was determined by Ouchterlony gel diffusion analysis using antisera directed against rat IgG subclasses, kindly supplied by Dr. H. Bazin (Catholic University, Louvain, Belgium).

Purification of IgG and Its Fragments from SER-4. SER-4 was grown as an ascites in pristane-primed AO rats, and the IgG was purified by sodium sulphate precipitation and anion-exchange chromatography using DEAE-Sephacel (Pharmacia Fine Chemicals). F(ab')\textsubscript{2} and Fab fragments were prepared as described by Rousseaux et al. for rat IgG2a (16). Purity of IgG, F(ab')\textsubscript{2}, and Fab was >95% when assessed by SDS-PAGE and Coomassie Brilliant Blue.
staining, using 10% acrylamide gels under reducing and nonreducing conditions. Protein concentrations were determined by measuring absorbance at 280 nM, assuming an extinction coefficient of 1.4.

**Comparison of SER Expression with SER-4 Ag.** TPM were plated at 10³/well in 96-well tissue culture microtiter plates in the defined serum-free medium, HB102 (New England Nuclear, Boston, MA) and allowed to adhere for 90 min. This and subsequent incubations were at 37°C and 5% CO₂ in a fully humidified incubator. Supernatants were removed and replaced with HB102 medium containing mouse serum at 20, 5, or 0%. SER assays were carried out in quadruplicate on days 0, 1, 2, and 4. Rosettes were fixed in 0.125% glutaraldehyde for 10 min and permeabilized in methanol for 30 min. The relative numbers of sheep E bound/well were determined by measuring the pseudoperoxidase activity of hemoglobin (17), as follows. PBS containing 10 mM imidazole, 0.5 mg/ml diaminobenzidine (DAB), and 0.02% H₂O₂ (pH 7.4), was added to wells. After 1 h at room temperature absorbance of the reaction product was measured at 410 nm on a Titertek plate reader (Dynatech Laboratories, Inc., Alexandria, VA).

To determine the number of cells in each well, the nuclei of methanol-fixed TPM in separate wells were stained for 1 min with 1% crystal violet in 70% methanol, followed by extensive rinsing with tap water. The absorbance at 570 nm was determined on the Titertek plate reader and converted to cell number using a linear standard curve, obtained by plating serial dilutions of TPM. The relative number of sheep E bound per MÖ was calculated and expressed as an E/MÖ index = OD (DAB)/OD (Crystal violet).

The remaining wells on each row were used for determination of SER-4 Ag site number. Wells were rinsed with FCS, air dried, and the plates were stored desiccated at −20°C. Immediately before assay, TPM were fixed for 10 min in methanol and nonspecific binding sites blocked by incubation in 10% rat serum for 30 min. Wells were incubated for 60 min at 4°C with 50 µl of a predetermined saturating concentration (10 µg/ml) of ¹²⁵I-SER-4 Fab, specific activity 1.3 µCi/µg; labeled by the chloramine T method (18). Specific binding was determined by subtracting counts from separate wells that had been preincubated with 30 µg/ml unlabeled SER-4 IgG before addition of ¹²⁵I-SER-4 Fab. As an internal control for site number analysis, binding assays were also carried out with ¹²⁵I-Fab fragments of the anti-CR3 mAb, 5C6, provided by Dr. H. Rosen (19). Bound radioactivity was solubilized in 0.5% NaOH and counted in a Packard 5210 gamma counter.

**Immunocytochemistry.** In preliminary experiments the antigenic determinant recognized by mAb SER-4 was destroyed by the fixatives glutaraldehyde and paraformaldehyde but not ethanol, methanol, or acetone. 7-μM cryostat sections were therefore fixed for 10 min in acetone at room temperature and stained with a 1:5 dilution of hybridoma tissue culture supernatant using an avidin-biotin-peroxidase detection kit (Vectastain; Vector Laboratories, Peterborough, UK). Negative controls included omission of first antibody and use of rat mAbs directed to unrelated Ag.

**Immunoprecipitation.** ¹⁰⁵TPM were cultured for 2 d in 10-cm diameter tissue culture petri dishes at a concentration of 10⁶/ml in DME + 10% mouse serum. For metabolic labeling, the medium was changed to methionine- and cysteine-free Eagle's medium with 10% mouse serum that had been desalted into the same medium using PD-10 columns (Pharmacia Fine Chemicals). [³⁵S]Methionine and [³⁵S]cysteine were each added at 25 µCi/ml, final concentration, and the cells were incubated for a further 16 h. For surface labeling, TPM, adherent to 10-cm diameter dishes, were iodinated by the lactoperoxidase-glucose oxidase method for 30 min at 4°C (20). After either method of labeling, TPM were washed extensively and solubilized in 10 mM Tris lysis buffer, pH 8.0, containing 150 mM NaCl, 2% NP-40, 2 mM PMSF, 5 mM EDTA, 5 mM iodoacetamide, 100 µg/ml soybean trypsin inhibitor, 1 µg/ml pepstatin, and 0.5% BSA. Nuclei and other insoluble materials were removed by centrifugation at 10,000 g and immunoprecipitations carried out as described (19). The samples were electrophoresed on 6.5% polyacrylamide gels according to Laemmli (21). ¹⁴C-methylated protein molecular weight markers (code CFA 626) were obtained from Amersham International PLC.

**Western Blots.** TPM were cultured for 3 d and lysates were prepared as described above. Spleen, mesenteric lymph nodes, thymus, and femoral bone marrow plugs were obtained
from a single mouse and added to 1 ml of 10 mM Tris, pH 8.0, containing 150 mM NaCl and protease inhibitors. The tissues were disrupted using an electrically driven homogenizer (Polytron; Kinematica GmbH, Lucerne, Switzerland) and solubilized by addition of an equal volume of nonreducing 2x SDS-PAGE sample buffer. Reduction with β-mercaptoethanol resulted in loss of antigenic activity. After removal of insoluble material by centrifugation at 10,000 g, 35 μl of the lysates were electrophoresed on 6.5% polyacrylamide gels. Proteins were transferred to nitrocellulose as described (22) and probed with 0.5 μg/ml 125I-SER-4 IgG, prepared by the chloramine T method (18). Specificity was determined by comparing the signals obtained in the presence or absence of 100-fold excess of unlabeled SER-4 IgG.

**Results**

Isolation of an mAb Directed to SER. To obtain an mAb to SER, our strategy was to immunize rats with mouse serum-induced TPM expressing high levels of SER, as determined by sheep E binding, and then to screen hybridoma supernatants for their ability to block sheep E binding to induced TPM (11). From a total of four fusions, one positive hybridoma was identified and designated SER-4. Tissue culture supernatant from SER-4 was able to completely inhibit binding of sheep E to mouse serum-induced TPM (Fig. 1). Complete inhibition of sheep E binding was also observed with resident bone marrow MØ on which the hemagglutinin was first described (not shown). Inhibition of SER by SER-4 supernatant was not accompanied by visible signs of toxicity or changes in morphology.

SER-4 was cloned three times by limiting dilution and was found to secrete an mAb of the rat IgG2a subclass by Ouchterlony analysis. After purification, the intact immunoglobulin was able to inhibit sheep E binding completely at ~1 μg/ml (Fig. 2). In comparison, F(ab')2 fragments of SER-4 mAb gave a maximum of only 50-60% inhibition, while Fab fragments had no effect on rosetting, even at concentrations up to 100 μg/ml (Fig. 2). The failure of Fab to inhibit binding of sheep E was not due to its lower avidity, since at 40 μg/ml it completely inhibited binding of a saturating concentration (1 μg/ml) of SER-4 IgG to TPM. In addition, 125I-SER-4 Fab bound to induced TPM in a specific and saturable manner, with maximal binding at 10 μg/ml (not shown).

Comparison of Expression of SER with the SER-4 Ag. Our previous studies have demonstrated that the in vitro expression of SER on TPM can be regulated reversibly by mouse serum in a dose-dependent fashion (11). It was therefore of interest to compare the binding of sheep E with expression of the SER-4 Ag by TPM cultured in a range of mouse serum concentrations. Antigenic site number analysis was carried out by direct binding assay with 125I-SER-4 Fab on methanol-fixed TPM. This measures the total amount of SER-4 Ag, both intra- and extracellular. It can be seen in Fig. 3 that expression of SER and the SER-4 Ag were closely correlated throughout the course of the experiment. At the outset of culture, TPM bound an average of 4 × 10^4 SER-4 Fab molecules/cell and there was negligible binding of sheep E. The highest levels of both SER-4 Ag and SER expression were observed on day 2 of culture in 20% mouse serum. At this time TPM bound an average of ~10^6 SER-4 Fab molecules/cell, representing a 25-fold increase in antigenic site number. In comparison, levels of SER activity (sheep E binding) increased ~10-fold. As an internal control for the site number analysis, binding assays were also carried out with Fab fragments of 5C6 anti CR3 mAb (19). On day 2, TPM bound on average of 2 × 10^4 molecules of 125I-5C6-Fab, irrespective of the concentration of mouse serum used
Figure 1. Inhibition of SER by mAb SER-4. Phase contrast micrographs of rosetting assays with mouse serum-induced TPM in the absence (A) or presence (B) of SER-4 mAb tissue culture supernatant. TPM were cultured on glass coverslips for 3 d in 15% mouse serum to induce SER. They were then incubated for 1 h in the presence or absence of SER-4 mAb tissue culture supernatant. After extensive washing, sheep E were added at 0.5% vol/vol. After 30 min at 37°C unbound sheep E were removed and the preparations were fixed in 1% glutaraldehyde before examination. (A) The majority of TPM rosette intensely with sheep E. (B) Erythrocyte binding is completely inhibited after preincubation with SER-4 mAb tissue culture supernatant.

Figure 2. Inhibition of SER by mAb SER-4 IgG, F(ab')2, and Fab fragments. TPM were induced to express SER by culture in 15% mouse serum for 3 d on microtiter plates. Wells were incubated for 1 h with threefold serial dilutions of IgG, F(ab')2, or Fab, washed extensively, and assayed for sheep E binding. The data show mean values of duplicate wells. Similar results were obtained in three independent experiments.
for culture. This is in agreement with previous estimates of CR3 site number on MØ (23). After removal of serum after 48 h, the levels of SER-4 Ag and SER declined in parallel. These results support the notion that the Ag recognized by SER-4 mAb is either closely related to, or identical with, SER.

**Characterization of the Antigen Recognized by mAb SER-4.** After metabolic labeling of mouse serum–induced TPM with a mixture of $[^{35}S]$methionine and $[^{35}S]$cysteine, mAb SER-4 was found to immunoprecipitate two species of Ag determined by SDS-PAGE not seen with control mAb 1A10 (Fig. 4 A). Under reducing conditions there was a major band with apparent $M_r$ of $\sim 185 \times 10^3$ and a minor band at $\sim 175 \times 10^3$. Under nonreducing conditions, the apparent $M_r$ of each band was decreased by $\sim 15 \times 10^3$ indicating the presence of one or more intrachain disulphide bonds.

After $^{125}$I surface labeling of mouse serum–induced TPM, mAb SER-4 specifically immunoprecipitated a single species of Ag by SDS-PAGE, with an apparent $M_r$ of $\sim 185 \times 10^3$ (reduced) (Fig. 4 B) or $\sim 170 \times 10^3$ (nonreduced) (not shown). Since the lower $M_r$ species observed after metabolic labeling was not detected with surface labeling, it is likely to be an incompletely processed form of the molecule that is absent from the plasma membrane.

To determine whether the SER-4 Ag was one of the forms of the LC Ag (24) we carried out immunoprecipitations with a pan anti-LC mAb, M1/9.3 (12). Following surface labeling with $^{125}$I, the LC Ag ran under reducing conditions on SDS-PAGE as a broad band with a $M_r$ ranging from 155 to $180 \times 10^3$. This was clearly distinct
from the SER-4 Ag immunoprecipitated from the same lysate and run on the same gel (Fig. 4 B). This demonstrates that the SER-4 Ag is not a member of the LC Ag family.

Distribution of SER-4 Ag In Vivo. In a previous study it was shown that expression of SER, assessed by rosette analysis, was restricted to certain subpopulations of stromal tissue MØ, especially those isolated from hematopoietic and lymphoid tissues. It was therefore important to compare the pattern of SER expression with the immunocytochemical distribution of SER-4 Ag in various tissues.

First, in cryostat sections of bone marrow plugs, mAb SER-4 revealed an arborizing network of stromal cells that were evenly distributed throughout the tissue (Fig. 5 A). These cells had the morphological features of resident bone marrow MØ (1, 6-8), and were intimately associated with hematopoietic cells. Immunofluorescence double-labeling experiments with the MØ-specific mAb, F4/80 (18), confirmed that SER-4+ cells were also F4/80+ (not shown). However, bone marrow monocytes, which label with F4/80, were not stained by SER-4. The selectivity of mAb SER-4 for the resident MØ population is consistent with previous rosetting experiments in which the resident MØ were shown to be the only bone marrow cells, including monocytes, able to bind sheep erythrocytes (9).
Figure 5. Photomicrographs of SER-4 Ag expression in situ. 7-μM cryostat sections were fixed in acetone and stained with the avidin-biotin immunoperoxidase method. (A) Bone marrow plug showing network of SER-4+ plasma membrane processes of the resident bone marrow MØ population. Monocytes and other developing hematopoietic cells are negative. (B) Mesenteric lymph node showing intense staining of stromal MØ in subcapsular sinus (arrowhead) and medullary cords (arrows). (C) Spleen showing intensely positive SER-4+ marginal metallophilis at periphery of white pulp (arrows), with weaker staining on MØ in the marginal zone and red pulp. (D) Liver showing SER-4+ sinus-lining Kupffer cells. Bars, 25 μM.
In lymph nodes, either mesenteric (Fig. 5 B), cervical or popliteal (not shown), intense staining was observed on stromal \( \text{MØ} \) in the subcapsular sinus and medullary cords, but tingible body \( \text{MØ} \) present in follicles were not stained. In some follicles, however, SER-4 revealed a reticular staining pattern within the developing germinal centers. The anatomical location and appearance of this staining pattern suggest that follicular dendritic cells may also be SER-4\(^+\) (25).

In the spleen, strong reactivity was observed on very stellate cells within the inner region of the marginal zone (Fig. 5 C). Weaker, but easily detectable staining was also present on marginal zone and red pulp \( \text{MØ} \) (Fig. 5 C). Examination under high power showed that the most strongly staining cells were on the follicular side of the marginal sinus. They can therefore be identified as marginal metallophilis, a specialized subpopulation of spleen \( \text{MØ} \) (26, 27). In support of this conclusion, we found that MOMA-1, a rat mAb that specifically recognizes mouse marginal metallophilis (13), produced a staining pattern in the spleen that was indistinguishable from that of SER-4 (not shown). In contrast to the other lymphoid tissues, the thymus showed no detectable staining with SER-4 (not shown).

In the liver, Kupffer cells were found to stain weakly, but uniformly with SER-4 (Fig. 5 D). In the lung, the stellate interstitial \( \text{MØ} \) stained strongly with SER-4 and

\[ \text{SER-4} \]

**FIGURE 6.** Western blots of SER-4 Ag expression in nonreduced lysates of mouse serum-induced TPM, spleen, lymph nodes, thymus, and bone marrow. Blots were prepared from 6.5% gels and probed with \( ^{125}\text{I}-\text{SER-4 IgG} \) in the absence or presence (left panel) of 100-fold excess unlabeled SER-4 IgG. A specific band at \( \sim 170 \times 10^3 \text{ M}_r \) can be seen in lysates of mouse serum-induced TPM, spleen, lymph node, and bone marrow, but not thymus. The weak signal observed in bone marrow lysates reflects the fact that lysates were normalized for organ input, rather than cell number. The positions of molecular weight standards (\( \times 10^{-3} \)) are indicated.
a subpopulation of bronchoalveolar MØ was also positive (not shown). In the skin, no reactivity was observed on epidermal Langerhans cells, though scattered dermal histiocytes were strongly positive (not shown). In the small intestine, occasional MØ in the lamina propria were stained and stromal MØ underlying the dome epithelium of Peyer's patches were also positive (not shown). In the kidney, virtually no MØ or other cell populations reacted with SER-4 (not shown). Finally, in the brain, microglia in the white and grey matter were completely negative for SER-4. Interestingly, however, the majority of MØ outside the blood brain barrier (28), in the choroid plexus, pituitary gland, subfornical organ, and leptomeninges, were clearly positive (not shown).

**Nature of SER-4 Ag in Tissues.** Western blot analyses were carried out to determine the nature of the Ag recognized by mAb SER-4 in hematopoietic and lymphoid tissues (Fig. 6). With nonreduced lysates of mouse serum-induced TPM, used as a control, 125I-SER-4 IgG specifically bound a 170-kD molecule (Fig. 6). Indistinguishable bands at 170 kD were seen for spleen, lymph node, and bone marrow, but no band was visible in the thymus (Fig. 6). The rank order (normalized on an organ, rather than cell number basis) was lymph node > spleen > bone marrow. The relative amount of SER-4 Ag for each tissue is therefore in agreement with the overall intensity of staining observed by immunocytochemistry.

**Discussion**

In this study we described the isolation and characterization of an mAb directed to SER, a novel MØ receptor that binds unopsonized sheep E via recognition of sialylated glycoconjugates (9). Our strategy, to screen for mAbs that inhibit receptor function, is a powerful selection method that has been used previously to isolate mAbs to FcR, fibronectin receptor, and other adhesion receptors on MØ (19, 29, 30).

Several lines of evidence indicate that the molecule recognized by mAb SER-4 is equivalent to SER, defined previously by rosetting studies. First, the time course of expression of the Ag on peritoneal MØ cultured in mouse serum closely parallels that of SER. Second, the distribution of the Ag in situ is consistent with previous rosetting studies of SER expression on isolated tissue MØ populations (9). Third, recent experiments in our laboratory indicate that the purified molecule specifically agglutinates sheep E (Crocker, P., unpublished observations).

It is likely that mAb SER-4 is directed close to, but not at, the putative sialic acid binding site of the receptor, since only 50% inhibition was obtained with F(ab')2 fragments while Fab fragments had no effect on SER function, despite binding effectively to the SER-4 Ag. This pattern of inhibition is compatible with steric hindrance such that the degree of inhibition is proportional to the size of the mAb fragment. However, we cannot exclude a partial role for MØ Fc receptors in mediating the inhibition by intact IgG.

The molecular properties and tissue distribution of the SER-4 Ag suggest that it is a previously uncharacterized differentiation Ag of mononuclear phagocytes. Immunoprecipitation and Western blotting experiments demonstrated that the SER-4 Ag is synthesized by MØ as a single-chain plasma membrane protein that on SDS-PAGE has an apparent $M_t$ of $185 \times 10^3$ under reducing conditions and $170 \times 10^3$ under nonreducing conditions. Despite the similarity in $M_t$ to the LC Ag family of molecules, the SER-4 Ag was shown to be distinct from members of this family expressed on the same MØ (24). The SER-4 Ag is of similar $M_t$ to several other...
single chain lectin-like receptors present in eukaryotic cells. These include the mannose receptor (175 kD) and the cation-independent mannose-6-phosphate receptor (215 kD), both of which are expressed on MØ as well as other cell types (31–33). However, SER can be distinguished from both molecules on the bases of ligand specificity, behavior on SDS-PAGE, and tissue distribution (31–33).

The SER-4 Ag was found to be present at high levels on subpopulations of stromal tissue macrophages. The pattern of expression was in agreement with earlier sheep E rosetting assays for SER (9). Thus, in the bone marrow, SER-4 Ag was restricted to the resident bone marrow MØ population, with none being detected on the developing F4/80* monocytes. Particularly striking was the high level of expression by the majority of stromal MØ in lymph nodes that also rosette intensely with sheep E (9). The spleen showed a more complex pattern of reactivity for SER-4, with high levels observed only on marginal metallophilis. Lesser, but clear staining was detected on MØ in the red pulp and the outer marginal zone. Since the majority of stromal MØ isolated from the spleen by collagenase digestion are from the red pulp and marginal zone (34, 35), the immunocytochemical staining pattern observed in the present study is consistent with previous rosetting analyses in which isolated stromal spleen MØ expressed moderate levels of SER (9).

Site number analysis of SER expression by TPM cultured in mouse serum showed that an average of up to \(10^6\) molecules of SER-4 Ag were expressed per cell. Although \(>50\%\) of this is intracellular (Crocker, P., unpublished observations), it is clear that when compared with other well-characterized plasma membrane receptors such as mannose receptor, CR3 and FcR, SER is potentially one of the most highly expressed MØ-restricted surface molecules described to date.

How can the heterogeneity of SER expression on MØ populations be explained? We have recently demonstrated that the induction and maintenance of SER on MØ in vitro is regulated in a dose-dependent manner by a species-restricted activity in mouse plasma and lymph (11). The activity in plasma had an apparent \(M_r\) of \(\sim 70 \times 10^3\) by gel filtration and this led us to propose that the heterogeneity of SER expression on different MØ populations could in part be explained by the relative concentration of inducing activity in different tissue compartments. In the present study, clear evidence for this possibility was seen in the central nervous system, where microglia within the blood brain barrier expressed no detectable SER-4 Ag, whereas MØ outside the blood brain barrier, in the choroid plexus and subfornical organ, expressed relatively high levels (28). Likewise, the absence of the SER-4 Ag on thymic MØ may be related to the presence of nonleaky endothelium in the cortex of this organ, creating a “blood-thymus barrier” (36).

It is clear, however, that there are additional mechanisms that regulate the level of the SER-4 Ag, because sinus-lining MØ in liver and spleen express intermediate levels, although they are continuously exposed to plasma. Since these MØ populations are important in the removal of effete E and since circulating mouse E express a sialylated ligand for SER (Crocker, P., unpublished observations), ingestion of effete E by these MØ could result in internalization and degradation of the SER-4 Ag.

The availability of an inhibitory mAb to SER will be a valuable tool in future studies investigating the functional significance of the receptor on MØ populations. The distribution of SER on selected populations of stromal tissue MØ is consistent with a role in cell-cell or cell-matrix interactions. Unlike other well-defined MØ lectin-like receptors, such as the mannose and galactose receptors (37, 38), SER does not
mediate phagocytosis of ligand-bearing particles and its primary function is therefore unlikely to be related to scavenging. If SER is involved in adhesive interactions in tissues such as bone marrow and lymph nodes, it should be possible to identify ligands on cells that are naturally associated with SER-4+ stromal MØ. Direct support for this possibility has come from our recent studies in which subpopulations of mouse bone marrow cells were shown to bind stably to SER + MØ in a manner indistinguishable from that of sheep E (Crocker, P., unpublished observations). In lymph nodes, SER-4+ MØ in subcapsular sinuses and medullary cords interact with recirculating lymphocytes and plasma cells, respectively (25), and marginal metallophil of the spleen are thought to bind avidly to B lymphocytes (27).

It is therefore possible that SER contributes to local adhesive interactions that influence the movement of bone marrow cells and recirculation of lymphocytes. In addition, the finding that sialic acid binding proteins can be mitogenic for B and T lymphocytes raises the interesting possibility that SER is involved in growth regulation of attached cells via direct cellular signaling (39, 40).

Summary

An inhibitory rat mAb, SER-4, has been raised to the mouse macrophage (MØ)-restricted hemagglutinin, sheep erythrocyte receptor (SER), which binds unopsonized sheep erythrocytes through recognition of sialylated glycoconjugates. This receptor was originally defined on mouse resident bone marrow MØ where it was implicated in adhesive interactions of these cells with proliferating hematopoietic cells. In the present study using mouse serum-induced thioglycollate-elicited peritoneal MØ (TPM) as a model system for SER expression, mAb SER-4 IgG2a completely blocked rosette formation at 1 μg/ml. The inhibition was likely to be via steric hindrance rather than through a direct interaction with the putative sialic acid binding site of SER because F(ab')2 and Fab fragments of mAb SER-4 gave a maximum inhibition of 50–60% and 0% respectively, despite binding effectively to the SER-4 antigen (Ag). Immunoprecipitation and Western blotting experiments with cultured MØ or tissue extracts demonstrated that the Ag recognized by SER-4 mAb is a single chain molecule with an apparent Mr by SDS-PAGE of 185 × 10^3 (reduced) or 170 × 10^3 (non-reduced) and is distinct from members of the leukocyte common Ag family. Expression of SER and SER-4 Ag in culture were closely correlated and depended on the presence of mouse serum for optimal induction. Further evidence that the SER-4 Ag is functionally equivalent to SER was provided by immunocytochemistry in which the overall pattern of staining in tissues was consistent with previous rosetting experiments. In the bone marrow, expression of the SER-4 Ag was restricted to the resident bone marrow MØ population with no expression on monocytes. High expression was also observed on stromal MØ within the subcapsular sinus and medullary cords in lymph nodes and on marginal metallophil in the spleen. These results therefore confirm that SER is a novel MØ-restricted receptor whose distribution and properties indicate a role in cellular interactions in hematopoietic and lymphoid tissues.

Received for publication 28 November 1988.

References

1. Hume, D. A., A. P. Robinson, G. G. MacPherson, and S. Gordon. 1983. The immunohistochemical localisation of antigen F4/80. The relationship between macrophages, Lang-
erhans cells, reticular cells and dendritic cells in lymphoid and hematopoietic organs.

2. Dijkstra, C. D., E. Van Fleit, E. A. Dopp, A. A. Van der Lelij, and G. Kraal. 1985. Marginal zone macrophages identified by a monoclonal antibody. Characterisation of immuno- and enzyme histochemical properties and functional capacities. *Immunology*. 55:23.

3. Kraal, G., M. Rep, and M. Janse. 1987. Macrophages in T and B cell compartments and other tissue macrophages recognised by monoclonal antibody MOMA-2. An immunohistochemical study. *Scand. J. Immunol.* 26:653.

4. Dijkstra, C. D., E. A. Dopp, P. Joling, and G. Kraal. 1985. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in rat recognised by monoclonal antibodies ED1, ED2 and ED3. *Immunology*. 54:589.

5. Buckley, P. J., M. R. Smith, M. F. Braverman, and S. A. Dickson. 1987. Human spleen contains phenotypic subsets of macrophages and dendritic cells that occupy discrete microanatomic locations. *Am. J. Pathol.* 128:505.

6. Lee, S. H., P. R. Crocker, S. Westaby, N. Key, D. Y. Mason, S. Gordon, and D. J. Weatherall. 1988. Isolation and immunocytochemical characterisation of human bone marrow stromal macrophages in hemopoietic clusters. *J. Exp. Med.* 168:1193.

7. Crocker, P. R., and S. Gordon. 1985. Isolation and characterization of resident stromal macrophages and hematopoietic cells clusters from mouse bone marrow. *J. Exp. Med.* 162:993.

8. Bessis, M., C. Mize, and M. Prenant. 1978. Erythropoiesis: comparison of in vivo and in vitro amplification. *Blood Cells*. 4:155.

9. Crocker, P. R., and S. Gordon. 1986. Properties and distribution of a lectin-like hemagglutinin differentially expressed by stromal tissue macrophages. *J. Exp. Med.* 164:1862.

10. Riedl, M., O. Förster, H. Rumpold, and H. Bernheimer. 1982. A ganglioside-dependent cellular binding mechanism in rat macrophages. *J. Immunol.* 128:1205.

11. Crocker, P. R., M. Hill, and S. Gordon. 1986. Regulation of a murine macrophage haemagglutinin (sheep erythrocyte receptor) by a species-restricted serum factor. *Immunology*. 65:515.

12. Springer, T., G. Galfré, D. S. Secher, and C. Milstein. 1978. Monoclonal xenogenic antibodies to murine cell surface antigens: identification of novel leukocyte differentiation antigens. *Eur. J. Immunol.* 8:539.

13. Kraal, G., and M. Janse. 1986. Marginal metallophilic cells of the mouse spleen identified by a monoclonal antibody. *Immunology*. 58:665.

14. Berton, G., H. Rosen, R. A. B. Ezekowitz, P. Bellavite, M. C. Serra, F. Rossi, and S. Gordon. 1986. Monoclonal antibodies to a particulate superoxide-forming system stimulate a respiratory burst in intact guinea pig neutrophils. *Proc. Natl. Acad. Sci. USA.* 83:4002.

15. Galfré, G., C. Milstein, and B. Wright. 1979. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. *Nature (Lond).* 277:131.

16. Rousseaux, J., R. Rousseaux-Prevost, and H. Bazin. 1983. Optimal conditions for the preparation of Fab and F(ab)2 fragments from monoclonal IgG of different rat IgG subclasses. *J. Immunol. Methods.* 64:141.

17. Jungi, T. W. 1985. A rapid and sensitive method allowing photometric determination of erythrophagocytosis by mononuclear phagocytes. *J. Immunol. Methods.* 82:141.

18. Austyn, J. M., and S. Gordon. 1981. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. *Eur. J. Immunol.* 11:805.

19. Rosen, H., and S. Gordon. 1987. Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells in vitro and inflammatory cell recruitment in vivo. *J. Exp. Med.* 166:1685.

20. Jeffreys, W. A., M. R. Brandon, A. F. Williams, and S. V. Hunt. 1985. Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. *Immunology*. 54:333.
21. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.). 227:680.

22. Towbin, H., F. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA. 76:4350.

23. Lee, S. H., P. Crocker, and S. Gordon. 1986. Macrophage plasma membrane and secretory properties in murine malaria. Effects of Plasmodium yoelii blood stage infection on macrophages in liver, spleen and blood. J. Exp. Med. 163:54.

24. Thomas, M. L., and L. Lefrancois. 1988. Differential expression of the leukocyte-common antigen family. Immunol. Today. 9:320.

25. Fossum, S., and W. L. Ford. 1985. The organisation of cell populations within lymph nodes: their origin, life history and functional relationships. Histopathology. 9:469.

26. Snook, T. 1964. Studies on the perifollicular region of the rat's spleen. Anat. Rec. 148:149.

27. Matsuno, K., H. Fuji, and M. Kotani. 1986. Splenic marginal-zone macrophages and marginal metallophilic in rats and mice. Cell Tissue Res. 246:263.

28. Perry, V. H., and S. Gordon. 1988. Macrophages and microglia in the nervous system. Trends Neurosci. 11:273.

29. Unkeless, J. C. 1979. Characterisation of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med. 150:580.

30. Hosein, B., and C. Bianco. 1985. Monocyte receptors for fibronectin characterised by monoclonal antibody that interferes with receptor activity. J. Exp. Med. 162:157.

31. Wileman, T. E., M. R. Lennartz, and P. D. Stahl. 1986. Identification of the macrophage mannose binding receptor as a 175-kDa membrane protein. Proc. Natl. Acad. Sci. USA. 83:2501.

32. Haltiwanger, R. S., M. A. Lehrman, A. E. Eckhardt and R. L. Hill. 1986. The distribution and localisation of the fucose-binding lectin in rat tissues and the identification of a high affinity form of the mannose/N-acetylglucosamine-binding lectin in rat liver. J. Biol. Chem. 261:7433.

33. Lobel, P., N. M. Dahms, and S. Kornfeld. 1988. Cloning and sequence analysis of the cation-independent mannose-6-phosphate receptor. J. Biol. Chem. 263:2563.

34. Humphrey, J. H., and D. Grennan. 1981. Different macrophage populations distinguished by means of fluorescent polysaccharides. Recognition and properties of marginal zone macrophages. Eur. J. Immunol. 11:221.

35. Nugrat, A. R., S. D. Wright, A. A. Aderem, R. M. Steinman, and Z. A. Cohn. 1988. Properties of isolated red pulp macrophages from mouse spleen. J. Exp. Med. 168:1505.

36. Raviola, E., and M. J. Karnovsky. 1972. Evidence for a blood thymus barrier using electron-opaque tracers. J. Exp. Med. 136:466.

37. Stahl, P. D., P. H. Schlesigner, E. Sigardson, J. S. Rodman, and Y. C. Lee. 1980. Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages. Characterisation and evidence for receptor recycling. Cell. 19:207.

38. Roos, P. H., H.-J. Hartman, J. Schlepper-Schafer, H. Kolb, and V. Kolb-Bachofen. 1985. Galactose-specific receptors on liver cells. II. Characterisation of the purified receptor from macrophages reveals no structural relationship to the hepatocyte receptor. Biochem. Biophys. Acta. 847:115.

39. Anders, E. M., A. A. Scalzo, G. N. Rogers, and D. O. White. 1986. Relationship between mitogenic activity of influenza viruses and the receptor-binding specificity of their haemagglutinin molecules. J. Virol. 60(V):476.

40. Dixon, S. J., D. Stewart, S. Grinstein, and S. Spiegel. 1987. Transmembrane signaling by the B subunit of cholera toxin: increased cytoplasmic free calcium in rat lymphocytes. J. Cell. Biol. 105:1153.